Chronic Lymphocytic Leukemia
The role of BTK monotherapy
Bcl-2 inhibitor combinations
Biology and clonal evolution of CLL
Cellular therapies for CLL
Monoclonals and bispecifics in CLL
Novel approaches to Richter’s transformation
Huang et al., Front Cell Dev Biol. 2021
Multiple Myeloma
Smoldering myeloma and special populations
T-cell engagers in MM
CAR-T for MM
Predictive biomarkers and precision therapy
Van de Donk et al., Lancet Oncol. 2021
Lymphoma
Chemo-free therapy for DLBCL
Peripheral T-cell lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Waldenström macroglobulinemia
Follicular lymphoma
Hodgkin Lymphoma
Uncommon lymphoma subtypes
Bispecifics as monotherapy in B-cell lymphoma
Combination therapy for B-cell lymphoma
Mihalyova et al., Int J Mol Sci. 2021
Leukemia and MDS/MPN
Acute myeloid leukemia
Acute lymphoblastic leukemia
Translational biology of AML, MDS, and MPN
Molecularly targeted therapies for AML, ALL, and MPN Myelofibrosis
Mastocytosis
Hairy cell leukemia
Chronic neutrophilic leukemia
Large granular lymphocyte leukemia
Gurney and O’Dwyer, Cancers. 2021
DAVA Oncology
PMB Box # 108, 5930 Royal Ln, Ste E, Dallas, TX 75230